Clinical Trials Using CD138CAR-CD137/TCRzeta-expressing T Lymphocytes

Clinical trials are research studies that involve people. The clinical trials on this list are studying CD138CAR-CD137/TCRzeta-expressing T Lymphocytes. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • Autologous CAR138 T-cells in Treating Patients with Relapsed or Refractory Multiple Myeloma

    This phase I trial studies the side effects and best dose of autologous chimeric antigen receptor targeting CD138 antigen (CAR138) T cells in treating patients with multiple myeloma that has come back or does not respond to treatment. CAR138 T cells combines antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances and by stopping them from growing. T cells are special infection fighting blood cells that can kill other cells, including cancer cells or cells that are infected.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina